中文
EN
About us
Company Introduction
Corporate History
Business Introduction
Corporate Governance
Company Culture
Corporate Honors
R&D and Innovation
R&D System and Platforms
Innovation Strategy
Innovation Pipeline
Achievements
Products
Drug Products
Next-gen Therapies
APIs
Boranes
Services
CDMO
Project Collaboration
In-/Out-Licensing
Joint Venture
Sustainable
EHS
Energy
Quality
Supplier
News Center
2026
2025
2024
2023
2022
2021
Join Us
Talent Philosophy
Talent Development
Salary and Benefits
Campus Recruiting
Social Recruitment
Contact Us
Online Message
Blog Center
In 2026
In 2025
In 2024
In 2023
In 2022
In 2021
In 2020
In 2019
In 2018
In 2017
In 2016
Viwit 2025 Annual Shareholders’ Meeting Successfully Concluded | Focus on Innovation, Steady Progress
39th World No Tobacco Day | Smoke-Free Youth, Boundless Future — Science-Based Smoking Cessation Makes Health and Future Accessible
Viwit’s Video “Ten Years in China, Growing with Viwit” Wins Second Prize in 2025 Shandong Province Foreign Expert Video Competition
Viwit Wins JD.com “Innovation Marketing Award” | Dr. Keene Wei Invited to JD Health 10th Anniversary & 2026 JD Pharmacy Partner Conference
Dr. Keene Wei Named “Outstanding Entrepreneur” by Both Tengzhou City and Zaozhuang High-Tech Zone
Dr. Keene Wei Invited as Keynote Speaker at His Alma Mater Dartmouth College’s Dreyfus Lecture, Showcasing Chinese Pharmaceutical Innovation
Viwit Pharmaceuticals to Showcase at DCAT Week 2026, Invites Global Partners to New York
10
/
03
Dr. Keene Wei, President of Viwit, Invited to Speak at the 2026 In Vivo Cell Therapy Innovation Summit
28
02
Innovation Drives Development, Focus Makes a "Little Giant": Viwit Recognized as a National Specialized, Refined, Distinctive, and Innovative "Little Giant" Enterprise in the Seventh Batch!
29
01
Viwit Pharmaceuticals Co., Ltd. Embarks on a New Journey: Fully Focused on Innovation, Driving the Future with Insight and Science
Viwit Pharmaceuticals Granted "Radiation Safety License": A Dual Milestone in Compliance and Innovation
22
Advancing into a New Chapter: Viwit Pharma Officially Launches Frontier Exploration in Targeted Gene and Cell Therapies
19
Viwit Pharmaceuticals' Sterile Production Facility Successfully Passes U.S. FDA Inspection
11
06
Viwit Pharmaceutical's Phenylephrine Hydrochloride Injection Officially Receives Official Approval by China NMPA
Recently, Viwit Pharmaceuticals received ‘Drug Registration Certificate’ issued by China National Medical Products Administration (NMPA) for independently developed Phenylephrine Hydrochloride Injection, the approval number is H20249727. This signifies that the product has received official approval for the Chinese market and been recognized as having passed the generic drug consistency evaluation.
16
12
Search
中文
EN
